It's hypothesized that the transition from early protective JNK‑AP‑1 activity to late‑phase SASP‑driven pathology is caused by a stimulus‑dependent switch in AP‑1 dimer composition from c‑Jun/ATF2 to JunB/c‑Fos, which rewires enhancer binding to favor NF‑κB cooperation and p300‑mediated acetylation at SASP loci.
Mechanistic Model
Early JNK activation (0‑48 h) phosphorylates c‑Jun and ATF2, promoting c‑Jun/ATF2 dimers that bind antioxidant response elements and suppress p53‑dependent senescence 1. As inflammatory cytokines (TNF, IL‑1) accumulate, sustained JNK signaling induces expression of the phosphatase MKP‑1 inhibitor and reduces MKP‑1 activity, prolonging JNK phosphorylation of JunB and c‑Fos. JunB, whose transcription is amplified by IL‑1‑driven NF‑κB 4 5, preferentially pairs with c‑Fos to form JunB/c‑Fos dimers. These dimers exhibit higher affinity for κB‑adjacent AP‑1 sites found in enhancers of IL‑6, IL‑8 and other SASP genes. Co‑occupancy with NF‑κB p65 recruits p300, increasing H3K27ac and stabilizing an open chromatin state that maintains SASP transcription 3.
Predictions and Experimental Design
- Time‑resolved ChIP‑seq for c‑Jun, ATF2, JunB, c‑Fos, p65 and p300 in doxorubicin‑treated MEFs sampled at 0, 12, 24, 48, 72 and 96 h will show a shift from c‑Jun/ATF2‑p300 peaks at antioxidant genes to JunB/c‑Fos‑p65‑p300 peaks at SASP enhancers





























